share_log

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga ·  Mar 15 09:06

Gainers

  • Better Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million.
  • Madrigal Pharmaceuticals (NASDAQ:MDGL) shares moved upwards by 22.34% to $298.0. The market value of their outstanding shares is at $5.9 billion.
  • Akebia Therapeutics (NASDAQ:AKBA) stock rose 16.05% to $1.59. The market value of their outstanding shares is at $299.5 million. As per the press release, Q4 earnings came out yesterday.
  • Rallybio (NASDAQ:RLYB) shares increased by 15.98% to $1.85. The company's market cap stands at $69.9 million. The company's, Q4 earnings came out 3 days ago.
  • Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 15.6% to $5.78. The market value of their outstanding shares is at $4.6 million.
  • Vivos Therapeutics (NASDAQ:VVOS) stock rose 15.02% to $4.9. The market value of their outstanding shares is at $6.5 million.

Losers

  • SELLAS Life Sciences Gr (NASDAQ:SLS) stock decreased by 33.5% to $1.03 during Friday's pre-market session. The company's market cap stands at $44.7 million.
  • Lucy Scientific Discovery (NASDAQ:LSDI) shares fell 25.53% to $1.24. The market value of their outstanding shares is at $2.1 million.
  • Graphite Bio (NASDAQ:GRPH) shares decreased by 15.23% to $2.95. The company's market cap stands at $171.7 million.
  • Psyence Biomedical (NASDAQ:PBM) stock decreased by 10.06% to $1.43. The market value of their outstanding shares is at $19.1 million.
  • Geron (NASDAQ:GERN) stock declined by 9.41% to $3.07. The market value of their outstanding shares is at $1.6 billion.
  • First Wave BioPharma (NASDAQ:FWBI) stock fell 7.27% to $4.98. The market value of their outstanding shares is at $7.7 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment